» Articles » PMID: 20596672

Characterisation of a Multimeric Protein Complex Associated with ERp57 Within the Nucleus in Paclitaxel-sensitive and -resistant Epithelial Ovarian Cancer Cells: the Involvement of Specific Conformational States of Beta-actin

Overview
Journal Int J Oncol
Specialty Oncology
Date 2010 Jul 3
PMID 20596672
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Ovarian cancer is the second most frequently diagnosed malignancy of the reproductive system and is the leading cause of gynecological cancer mortality. Although the majority of advanced ovarian carcinomas initially respond successfully to taxane-based chemotherapy, resistance to chemotherapy remains the primary factor accounting for the low 5-year survival in this patient population. Recent data obtained by our group demonstrate that the disulphide isomerase ERp57 is strongly modulated in paclitaxel resistance suggesting that it may represent a chemoresistance biomarker in ovarian cancer. In the present study, we characterise a nuclear multimeric complex where ERp57 is associated with protein species involved in cell division and gene expression, as Nucleolin, Nucleophosmin, Vimentin, Aurora kinase C and beta-actin. In particular, we show that the occurrence of the interaction of nuclear ERp57 with beta-actin is associated with paclitaxel resistance and that specific actin conformations modulate this complex. We propose the involvement of the nuclear ERp57 complex in mechanisms associated with chromosome segregation in which specific conformational states of actin play a role in the pathway involved in paclitaxel resistance.

Citing Articles

In oxygen-deprived tumor cells ERp57 provides radioprotection and ensures proliferation via c-Myc, PLK1 and the AKT pathway.

Ocklenburg T, Neumann F, Wolf A, Vogel J, Gopelt K, Baumann M Sci Rep. 2021; 11(1):7199.

PMID: 33785835 PMC: 8009878. DOI: 10.1038/s41598-021-86658-5.


Insights into the role of ERp57 in cancer.

Song D, Liu H, Wu J, Gao X, Hao J, Fan D J Cancer. 2021; 12(8):2456-2464.

PMID: 33758622 PMC: 7974888. DOI: 10.7150/jca.48707.


Aurora kinases in ovarian cancer.

Perez-Fidalgo J, Gambardella V, Pineda B, Burgues O, Pinero O, Cervantes A ESMO Open. 2020; 5(5):e000718.

PMID: 33087400 PMC: 7580081. DOI: 10.1136/esmoopen-2020-000718.


Expression of protein disulfide isomerase family members correlates with tumor progression and patient survival in ovarian cancer.

Samanta S, Tamura S, Dubeau L, Mhawech-Fauceglia P, Miyagi Y, Kato H Oncotarget. 2017; 8(61):103543-103556.

PMID: 29262583 PMC: 5732749. DOI: 10.18632/oncotarget.21569.


Multifunctional molecule ERp57: From cancer to neurodegenerative diseases.

Hettinghouse A, Liu R, Liu C Pharmacol Ther. 2017; 181:34-48.

PMID: 28723413 PMC: 5743601. DOI: 10.1016/j.pharmthera.2017.07.011.